体外研究显示促凝双特异性抗体与旁路制剂具有协同效应
本研究通过体外实验评估艾美赛珠单抗序列相同类似物(SIA)单用或联合活化凝血酶原复合物浓缩物(aPCC)、重组活化凝血因子VII(rFVIIa)对凝血酶生成和血凝块形成的影响。SIA联合aPCC使凝血酶峰值较SIA单用升高17倍,超过参考血浆值4.2倍,提示联合用药时需谨慎判断。
要点
- SIA(600 nm)联合aPCC(0.5 U mL-1)使凝血酶峰值较SIA单用升高17倍。
- SIA联合aPCC的高凝效应在aPCC低至0.25 U mL-1时即可出现。
- SIA联合rFVIIa(1.75 μg mL-1)使血小板-rich血浆凝血酶峰值升高1.8倍,未达正常范围。
核心结论
- 体外实验表明,在临床相关剂量下联合使用aPCC与SIA会导致凝血酶生成过多。
- 对接受艾美赛珠单抗治疗的患者处理突破性出血时,可能需要仔细判断。
研究设计与样本
- 体外研究,评估SIA单用或联合aPCC、aPCC各分离成分或rFVIIa对凝血酶生成和血凝块形成的影响。
- SIA浓度为20-600 nm,aPCC浓度为0.05-1 U mL-1,rFVIIa浓度为0.88-5.25 μg mL-1。
- 使用旋转血栓弹力图(ROTEM)测定FVIII抑制血的凝血,并用Total Thrombus-formation Analysis System确认。
主要发现
- SIA(600 nm)单用时凝血酶峰值水平为21.4 nm,低于正常值(83.7 ± 29.8 nm)。
- aPCC(0.5 U mL-1)单用时凝血酶峰值水平为38.6 nm,低于正常值(83.7 ± 29.8 nm)。
- SIA联合aPCC(0.5 U mL-1)使凝血酶峰值水平较SIA单用升高17倍,超过参考血浆值4.2倍。
- SIA(600 nm)联合aPCC低至0.25 U mL-1时即出现高凝效应,并经ROTEM确认。
- FIX是增强凝血酶生成的主要驱动因素;SIA联合rFVIIa(1.75 μg mL-1)使血小板-rich血浆凝血酶峰值水平升高1.8倍,但未达正常范围。
临床怎么用
- 对接受艾美赛珠单抗治疗的患者处理突破性出血时,可能需要仔细判断。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Essentials Patients with hemophilia A and inhibitors receiving emicizumab experience breakthrough bleeding. Safety concerns may exist when combining emicizumab with bypassing agents. Combined bypassing agent and bispecific antibody increased thrombin generation up to 17-fold. Thrombotic effects should be considered when combining emicizumab with plasma bypassing agent. SUMMARY: Background Investigational non-factor products such as emicizumab offer a treatment option for patients with hemophilia and inhibitors. However, their mechanism of action raises questions regarding safety when they are combined with treatments for breakthrough bleeding. Objectives To evaluate in vitro thrombin generation (TG) and clot formation for combinations of activated prothrombin complex concentrate (aPCC), recombinant activated factor VII (rFVIIa), and a sequence-identical analog of emicizumab (SIA). Methods Therapeutic concentrations of SIA (20-600 nm) alone or with aPCC (0.05-1 U mL-1 ), isolated aPCC components or rFVIIa (0.88-5.25 μg mL-1 ) were tested for TG and compared with reference ranges for healthy donor plasma. Coagulation of FVIII-inhibited blood was determined with a widely established method, i.e. rotational thromboelastometry (ROTEM), and confirmed with the Total Thrombus-formation Analysis System. Results and conclusions SIA (600 nm) or aPCC (0.5 U mL-1 ) alone resulted in peak thrombin levels of 21.4 nm and 38.6 nm, respectively, both of which are lower than normal (83.7 ± 29.8 nm). SIA plus aPCC (0.5 U mL-1 ) increased the peak thrombin level 17-fold over SIA alone, exceeding the reference plasma value by 4.2-fold. This hypercoagulable effect occurred with 600 nmSIA combined with as little as 0.25 U mL-1 aPCC, confirmed by ROTEM. FIX was the main driver for enhanced TG. SIA plus rFVIIa (1.75 μg mL-1 ) induced a 1.8-fold increase in the peak thrombin level in platelet-rich plasma, but it did not reach the normal range. These in vitro experiments demonstrate excessive TG after administration of a combination of aPCC and SIA at clinically relevant doses. Careful judgement may be required when breakthrough bleeding is treated in patients receiving emicizumab.
引用
- Hartmann R, Feenstra T, Valentino L, et al. In vitro studies show synergistic effects of a procoagulant bispecific antibody and bypassing agents. J Thromb Haemost. 2018. PMID: 29888855. doi:10.1111/jth.14203
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。